Granted Patent B2

US 12,377,070 · App. 17/642,184 · Granted Aug 5, 2025

Inventors: Rajiv Sharma (Ahmedabad, IN); Sameer Agarwal (Ahmedabad, IN)

Assignee: Zydus Lifesciences Limited

A61K31/40A61K31/4025A61K31/427A61K38/2013A61K38/21A61K45/06C07D207/08C07D207/48C07D405/04C07D417/06

Abstract

Claims (50)

1. Compound(s) having structure of general formula (I)

their tautomeric forms, their stereoisomers, their enantiomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them wherein, ‘A’ is selected from optionally substituted groups selected from (C 3 -C 8 )cycloalkyl, (C 6 -C 10 )aryl, heteroaryl, and heterocyclyl groups each of which is optionally further substituted with one or more than one heteroatom(s);

B′ is the following ring system

R 1 at each occurrence is independently selected from hydrogen, halogen, haloalkyl, optionally substituted groups selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, (C 6 -C 10 )aryl, heterocyclyl, thiol, (C 1 -C 6 ) mercapto alkyl, SO 2 (C 6 -C 10 )aryl, SO 2 (C 3 -C 6 )cycloalkyl, C 1 -C 6 (thio-alkoxy), CO(O)(C 1 -C 6 )alkyl;

R 2 is hydrogen;

n is 0;

R 3 at each occurrence is independently selected from hydrogen, cyano, optionally substituted groups selected from (C 1 -C 10 )alkyl;

R 4 and R 5 are independently hydrogen.

2. The compound(s) as claimed in claim 1 , wherein when any of above defined group is substituted, the substitutions on them may be selected from those described above or may additionally be selected from hydrogen, hydroxy, cyano, halo, haloalkyl, haloalkyloxy, alkylthio (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —COR 12 , —CSR 12 , C(O)OR 12 , C(O)—R 12 , —C(O)—NR 12 R 13 , —C(S)—NR 12 R 13 , —SO 2 R 12 group, wherein each of R 12 and R 13 is independently selected from hydrogen, optionally substituted group selected from (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 7 )cycloalkyl, aryl, heteroaryl, heterocyclyl groups.

3. The compound as claimed in claim 1 is selected from the group comprising;

tert-butyl (2R)-2-((E)-2-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)pyrrolidine-1-carboxylate;

tert-butyl (28)-2-((E)-2-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)-2-methylpyrrolidine-1-carboxylate;

tert-butyl (2S)-2-((E)-2-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)-2-methylpyrrolidine-1-carboxylate;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide hydrochloride;

(E)-2-((S)-1,2-dimethylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-2-((S)-1,2-dimethylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methylethene-1-sulfonimidamide;

(E)-N′-cyano-2-((S)-1,2-dimethylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((R)-1-(cyclohexylsulfonyl) pyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((R)-1-((2-cyanophenyl) sulfonyl) pyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((R)-pyrrolidin-2-yl)ethene-1-sulfonimidamide hydrochloride;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((R)-1-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide;

tert-butyl (2R)-2-((E)-2-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)-2-methylpyrrolidine-1-carboxylate;

tert-butyl (2R)-2-((E)-2-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)-2-methylpyrrolidine-1-carboxylate;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((R)-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide hydrochloride;

(E)-N′-cyano-2-((R)-1,2-dimethylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

tert-butyl (2-((2S)-2-((E)-2-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)-2-methylpyrrolidin-1-yl)ethyl)(methyl) carbamate;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-1-isopropyl-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((S)-1-cyclopentyl-2-methylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((S)-1-cyclobutyl-2-methylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((S)-1-(cyclopropylmethyl)-2-methylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide 2,2,2-trifluoroacetate;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-2-methyl-1-(tetrahydro-2H-pyran-4-yl) pyrrolidin-2-yl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-1-isobutyl-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide;

(E)-2-((S)-1-acetyl-2-methylpyrrolidin-2-yl)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((S)-1-ethyl-2-methylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-2-((S)-1-cyclohexyl-2-methylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-1-(2-methoxyethyl)-2-methylpyrrolidin-2-yl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-2-methyl-1-(thiazol-2-ylmethyl) pyrrolidin-2-yl)ethene-1-sulfonimidamide;

(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-((S)-2-methyl-1-(2-methyl-2-(pyrrolidin-1-yl)propyl)pyrrolidin-2-yl)ethene-1-sulfonimidamide;

(2S)-2-((E)-2-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)-2-methylpyrrolidine-1-carboxamide;

sodium ((E)-N-cyano-2-((S)-1-isobutyl-2-methylpyrrolidin-2-yl)vinylsulfonimidoyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amide;

sodium ((E)-N-cyano-2-((S)-1-cyclohexyl-2-methylpyrrolidin-2-yl) vinylsulfonimidoyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amide;

tert-butyl (2R)-2-((E)-2-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)vinyl)pyrrolidine-1-carboxylate;

(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methyl-2-((R)-pyrrolidin-2-yl)ethene-1-sulfonimidamide 2,2,2-trifluoroacetate;

(E)-2-((S)-1,2-dimethylpyrrolidin-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methylethene-1-sulfonimidamide.

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1 and optionally one or more pharmaceutically acceptable carriers, diluents or excipients.

5. A method of treating diseases medicated by the NLRP3 modulators as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) are implicated, which comprise the step of administering to a patient in need thereof an effective amount of a compound of Formula (I) as claimed in claim 1 or its suitable pharmaceutical composition.

6. A method of treating a disease medicated by an NLRP3 modulator comprising the step of administering to a patient in need thereof an effective amount of a compound of Formula (I) as claimed in claim 1 , wherein the NLRP3 modulator has a pathophysiological function.

7. A method of treating a disease medicated by an NLRP3 modulator comprising the step of administering to a patient in need thereof an effective amount of a pharmaceutical composition as claimed in claim 4 , wherein the NLRP3 modulator has a pathophysiological function.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (15)